Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS

Alexandra C. Istl, Jessica M. Ruck, Carol D Morris, Adam Levin, Christian Meyer, Fabian Johnston

Research output: Contribution to journalReview article

Abstract

New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.

Original languageEnglish (US)
JournalJournal of Surgical Oncology
DOIs
StatePublished - Jan 1 2019

Keywords

  • chemotherapy
  • localized
  • resectable
  • soft tissue sarcoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS'. Together they form a unique fingerprint.

  • Cite this